Schroder Investment Management Group’s Adaptive Biotechnologies ADPT Stock Holding History

Schroder Investment Management Group’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-365,656	Closed	-$1.79M	–	1199
2023 Q4	$1.79M	Sell	365,656 -60,340	-14%	-$275K	﹤0.01%	924
2023 Q3	$2.32M	Sell	425,996 -47,789	-10%	-$316K	﹤0.01%	890
2023 Q2	$3.18M	Hold	473,785	–	–	﹤0.01%	865
2023 Q1	$4.18M	Hold	473,785	–	–	0.01%	820
2022 Q4	$3.62M	Buy	+473,785	New	+$3.69M	0.01%	838

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

AAP

Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Schroder Investment Management Group's ADPT Position: Q1 2024 in Review

Schroder Investment Management Group sold out of Adaptive Biotechnologies (ADPT) in Q1 2024, closing a stake of 365,656 shares — an estimated $1.79M sold.

Schroder Investment Management Group first reported a position in ADPT in Q4 2022 and held it in 5 quarters. The position peaked at $4.18M in Q1 2023. 190 funds tracked by Wall St. Rank hold ADPT as of Q1 2024.

Schroder Investment Management Group reported no remaining Adaptive Biotechnologies position as of Q1 2024 after selling out during the quarter.
Schroder Investment Management Group sold 365,656 Adaptive Biotechnologies shares in Q1 2024, an estimated $1.79M.
Schroder Investment Management Group first reported a position in Adaptive Biotechnologies in Q4 2022 and held it in 5 quarters.
Schroder Investment Management Group's Adaptive Biotechnologies position peaked at $4.18M in Q1 2023.
190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2024.

Based on Schroder Investment Management Group's 13F filing for Q1 2024, filed 14 May 2024.